Clinical trial · Interventional
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of conventional staging methods, radiation treatment planning and the assessment of tumor response in esophageal or esophagogastric cancer. This study aimed to explore the value of MRI for the prediction of tumor response to chemoradiotherapy and accurate target volume delineation as compared to CT simulation for patients with unresectable or potentially resectable esophageal or esophagogastric cancer undergoing chemoradiotherapy. The average CT texture features are also extracted before and during treatment to establish a model to predict the prognosis or side effects (e.g. radiation pneumonitis or esophagitis) of patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophagogastric Junction Cancer | — | UNRESOLVED | — |
| Esophagus Cancer | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI and CT | Device | — | UNRESOLVED |
| Paclitaxel, platinum-based drug | Drug | — | UNRESOLVED |
| Ratiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Esophageal or esophagogastric cancer
- interventionNames
- Device: MRI and CT
- Radiation: Ratiotherapy
- Drug: Paclitaxel, platinum-based drug
Primary outcomes (3)
- measure
- Tumor response based on MRI and CT simulation
- timeFrame
- up to 8 weeks
- measure
- Radiotherapy target volume assessment with pre- and post-chemoradiotherapy based on MRI and CT simulation
- timeFrame
- up to 8 weeks
- measure
- Evaluation of tumor heterogeneity with IBEX software
- timeFrame
- up to 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed squamous cell carcinoma, adenocarcinoma of the esophageal or esophagogastric junction * Unresectable or potentially resectable tumor (cT3-4N0-1M0-M1a, according to AJCC 6th) based on standard primary staging by EUS and CT * Age\>18 years * No distant metastasis other than supraclavicular lymph nodes * No prior history of thoracic radiation or chemotherapy * Patients must have normal organ and marrow function as defined below: Leukocytes: greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits * Informed consent Exclusion Criteria: * Contraindication for MRI scanning * Patients with other cancer history except cervical carcinoma in situ and non-malignant melanoma skin cancer * Pregnant or lactating females * Contraindication for radiotherapy or chemotherapy
References
Publications (0)
Data not yet available